Arentor DC 250 mg Intramammary Suspension for Dry Cows

Authorised

- Cefalonium dihydrate

Product identification

Medicine name:
Arentor DC 250 mg Intramammary Suspension for Dry Cows
Arentor DC 250 mg интрамамарна суспензия за сухостойни крави

Active substance:
Cefalonium dihydrate

Target species:
Cattle

Route of administration:
Intramammary use

Product details

Active substance and strength:
Cefalonium dihydrate
269.63 milligram(s) / 1.00 Syringe

Pharmaceutical form:
Intramammary suspension

Withdrawal period by route of administration:

Intramammary use:

- **Cattle**

  - Meat and offal. 21 day

  - Milk. 96 hour 96 hours after calving if the dry period is longer than 54 days

  - Milk. 58 day

58 days following the treatment if the dry period is less than or equal to 54 days

---

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ51DB90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Bulgaria

Package description:

A 3g coloured low density polyethylene intramammary syringe with a coloured low density polyethylene dual capPack sizes:Buckets of 120 intramammary syringes and 120 individually wrapped cleaning towelscontaining isopropyl alcohol.
A 3g coloured low density polyethylene intramammary syringe with a coloured low density polyethylene dual capPack sizes:Cartons of 20 intramammary syringes and 20 individually wrapped cleaning towels containing isopropyl alcohol.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Univet Limited

Marketing authorisation date:
9/12/2018

Manufacturing sites for batch release:
Univet Limited

Responsible authority:
Bulgarian Food Safety Authority

Authorisation number:
0022-2855

Date of authorisation status change:
9/12/2018

Reference member state:
Ireland

Procedure number:
IE/V/0389/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.
